🇺🇸 GW685698 in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Chronic Obstructive Pulmonary Disease — 7 reports (33.33%)
  2. Pneumonia — 4 reports (19.05%)
  3. Dysphonia — 2 reports (9.52%)
  4. Oesophageal Candidiasis — 2 reports (9.52%)
  5. Anaphylactoid Reaction — 1 report (4.76%)
  6. Angina Unstable — 1 report (4.76%)
  7. Aortic Aneurysm — 1 report (4.76%)
  8. Atrial Fibrillation — 1 report (4.76%)
  9. Atrial Flutter — 1 report (4.76%)
  10. Bladder Neoplasm — 1 report (4.76%)

Source database →

Other Immunology approved in United States

Frequently asked questions

Is GW685698 approved in United States?

GW685698 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for GW685698 in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.